We highlight notable data from this month's ASCO annual meeting.
1. SONIA: sequence (1st or 2nd-line) CKD 4/6i in MBC
2. ADAURA OS results and low rate of osimertinib use in control arm
3. Keynote 671: perioperative pembrolizumab in NSCLC
4. PROSPECT: Can radiation therapy be omitted in locally advanced rectal cancer?
5. Nivo-AVD vs. Bv-AVD in stage III Hodgkin's (ages 12+)
6. ZUMA-7: 2nd line Axl-Cel OS benefit in aggressive NHL (early relapse/refractory disease)
7. CARTITUDE-4: Cilta-Cel earlier in MM treatment
